HIV 치료제 시장 규모, 점유율, 성장 분석 : 약물 종류별, 약물 유형별, 유통 경로별, 지역별 - 업계 예측(2026-2033년)

Global HIV Drugs Market size was valued at USD 36.09 Billion in 2024 and is poised to grow from USD 37.68 Billion in 2025 to USD 53.17 Billion by 2033, growing at a CAGR of 4.4% during the forecast period (2026-2033).

The global market for HIV drugs is set for significant growth driven by the increasing prevalence of HIV infections. Rising awareness and demand for improved therapeutics are anticipated to further propel the market. Innovations in antiretroviral therapy (ART) are vital in enhancing treatment efficacy, contributing positively to market dynamics. Substantial investments aimed at developing advanced HIV treatments present lucrative opportunities for pharmaceutical providers. Additionally, government-led initiatives focused on HIV awareness and prevention are expected to support long-term sales growth. An increased emphasis on early testing and diagnostics may also expand business opportunities within the sector. However, challenges such as long-term treatment side effects, drug resistance, social stigma, and the high cost of some medications may impact the overall demand for HIV drugs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global HIV Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global HIV Drugs Market Segments Analysis

Global HIV Drugs Market is segmented by Medication Class, Drug Type, Distribution Channel and region. Based on Medication Class, the market is segmented into Multi-class Combination Drugs, Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Entry & Fusion Inhibitors, Protease Inhibitors (PIs), Integrase Inhibitors and Coreceptor Antagonists. Based on Drug Type, the market is segmented into Branded Drugs and Generic Drugs. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global HIV Drugs Market

The Global HIV Drugs market is witnessing significant momentum as governments and public health organizations actively implement support and awareness campaigns aimed at promoting HIV treatment. These initiatives enhance the accessibility of HIV medications for patients worldwide, particularly benefiting individuals in low to middle-income countries. By improving awareness and providing vital support, these programs aim to facilitate better treatment options and care for those affected by HIV, ultimately driving growth in the market. Increased collaboration and commitment from various stakeholders are likely to contribute to a more robust environment for HIV drug accessibility and treatment globally.

Restraints in the Global HIV Drugs Market

Drug resistance remains a significant challenge in the landscape of modern medicine, posing a substantial constraint on the growth of the HIV drugs market. One of the primary contributors to this issue is inconsistent adherence to medication, which leads to the emergence of drug-resistant HIV strains. This scenario curtails the available treatment options and complicates patient management strategies. As a result, healthcare providers are pressed to develop alternative therapeutic approaches, adding complexity to the overall market dynamics. Consequently, these factors collectively hinder the potential for advancement and expansion within the HIV drug sector.

Market Trends of the Global HIV Drugs Market

The Global HIV Drugs market is witnessing a significant shift towards dual therapy, driven by the need to enhance treatment efficacy while minimizing side effects associated with traditional antiretroviral regimens. This innovative therapeutic approach not only reduces the pill burden for patients but also lowers toxicity levels, making it a compelling option for both clinicians and patients seeking better quality of life. As pharmaceutical companies adapt to this trend, they are poised to expand their portfolios and capture a larger market share, ultimately leading to improved health outcomes in the fight against HIV and bolstering their competitive positioning in the industry.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Patent Analysis

Global HIV Drugs Market Size by Medication Class & CAGR (2026-2033)

• Market Overview
• Multi-class Combination Drugs
• Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
• Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
• Entry & Fusion Inhibitors
• Protease Inhibitors (PIs)
• Integrase Inhibitors
• Coreceptor Antagonists

Global HIV Drugs Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Branded Drugs
• Generic Drugs

Global HIV Drugs Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global HIV Drugs Market Size & CAGR (2026-2033)

• North America (Medication Class, Drug Type, Distribution Channel)
  • US
  • Canada
• Europe (Medication Class, Drug Type, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Medication Class, Drug Type, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Medication Class, Drug Type, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Medication Class, Drug Type, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ViiV Healthcare (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hetero Drugs (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Basilea Pharmaceutica (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Advanz Pharma (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Macleods Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark Pharmaceuticals (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations